W

hither Teva Pharmaceuticals (TEVA)?

After weeks of anticipation, the drug maker is starting a large-scale reorganization that involves 14,000 layoffs, or 25 percent of its workforce; closing or selling a “significant” number of 80 manufacturing plants; repricing or discontinuing some generics; closing or selling some R&D facilities and reviewing all R&D programs; and suspending dividends on ordinary shares and annual bonuses this year.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

X